Indeed, the presence of tumor-infiltrating lymphocytes is a prerequisite for responses to immune checkpoint inhibitors such as antibodies against CTLA-4, PD-1, and PD-L1 [35]. This evidence concerns the gene CTLA4 and neoplasm.